OKUR: onkuretherapeutics.com Kompaniya qiymatining sof foydaga nisbati

OnKure Therapeutics - OKUR emitenti grafik logotipi

OnKure Therapeutics Inc (OKUR) ishlanmalarining eksklyuzivligi qat'iy FDA tartiblari va molekulalarning patent himoyasi bilan kafolatlangan. Kompaniyaning ilmiy hamjamiyatdagi yuqori nufuzi genetik o'smalar nuqsonlariga yo'naltirilgan ta'sir ko'rsatuvchi dori vositalarini yaratishga asoslangan. Aktivning bozor qiymati dinamikasi, bunda P/E ko'rsatkichi -1.70 ni tashkil etadi, aniq inhibitorlarni ishlab chiqish uchun biofarmatsevtika markazlari bilan sinergiya yaratish strategiyasining muvaffaqiyatini tasdiqlaydi.

Narx-foyda koeffitsiyenti: OnKure (OKUR) 08.10.2024 - 18.11.2026 uchun

OnKure Therapeutics, Inc. (OKUR) boʻyicha keng qamrovli koʻrsatkichlar kesimi va tahlil

Kompaniyaning har tomonlama tahlili:OKUR (OnKure Therapeutics, Inc.)
OnKure Therapeutics yetakchi tovari

Emitent ishonchliligini tekshirishda, bozor kapitalizatsiyasi va sof foyda o'rtasidagi bog'liqlik sifatida P/E ko'rsatkichini tahlil qilish muhimdir, chunki u bir dollar foydaning tannarxini belgilaydi. Geopolitik to'siqlar va OnKure Therapeutics Inc (OKUR) uchun klinik sinovlar uzilishlari fonida, ushbu narx-foyda grafikasi onkologik dori vositalarini ishlab chiqishning sekinlashishi va logistik xatarlarga qaramay, bozorning kelajakdagi innovatsiyalar uchun qo'shimcha to'lov qilishga tayyorligini aniq ko'rsatmoqda.

Raqobatdosh kompaniyalar tahlili

ONC: Kompaniya qiymatining sof foydaga nisbati|Narx-foyda koeffitsiyenti HALO (Halozyme Inc.)|RVMD (RevMed) - Kompaniya qiymatining sof foydaga nisbati|P/E multiplikatori AAPG (ascentage.com)|CGON - Narx-foyda koeffitsiyenti|URGN: Narx-foyda koeffitsiyenti|BCAX - P/E multiplikatori|Personalis Corp (PSNL) - Narxning foydaga nisbati|Erasca Corp - Kompaniya qiymatining sof foydaga nisbati|DCTH (Delcath Systems Inc) - P/E multiplikatori|Kapitalizatsiyaning foydaga nisbati Y-mAbs Therapeutics, Inc. YMAB|P/E multiplikatori AURA|Narx-foyda koeffitsiyenti Candel Therapeutics, Inc. CADL|P/E multiplikatori ARAY (Accuray, Inc.)|SELLAS Life Sciences - Narxning foydaga nisbati|ACTU: Narx-foyda koeffitsiyenti|Citius Oncology, Inc. - Bozor narxining sof foydaga nisbati|HURA (TuHURA Biosciences) - Narx-foyda koeffitsiyenti|TARA: Bozor narxining sof foydaga nisbati|Narx-foyda koeffitsiyenti FATE|WHWK: Kompaniya qiymatining sof foydaga nisbati|Narx-foyda koeffitsiyenti TCRX (TScan Therapeutics Inc)|Biznesning o‘zini qoplash muddati Champions Oncology Inc|P/E multiplikatori XBIT (XBiotech Inc.)|Kompaniya qiymatining sof foydaga nisbati CVM|OS Therapies Inc. - P/E multiplikatori|RADX - P/E multiplikatori|ARTV: P/E multiplikatori|ANL: Bozor narxining sof foydaga nisbati|Narx-foyda koeffitsiyenti VERU|TPST: Kompaniya qiymatining sof foydaga nisbati|Narxning foydaga nisbati xiliotx.com (XLO)|Renovaro - Narx-foyda multiplikatori|Narxning foydaga nisbati Mural Oncology MURA|KAPA - Narx-foyda koeffitsiyenti|CytoMed Therapeutics - P/E multiplikatori|Biznesning o‘zini qoplash muddati Curis CRIS|APLM: P/E multiplikatori|Narx-foyda koeffitsiyenti Tharimmune, Inc.|ADVB (Advanced Biomed) - P/E multiplikatori|Genprex - Kapitalizatsiyaning sof foydaga nisbati|Narxning foydaga nisbati calidibio.com (CLDI)|SBFM (Sunshine Biopharma Inc.) - Kompaniya qiymatining sof foydaga nisbati|P/E multiplikatori XBIO (Xenetic Biosciences)|Salarius Pharmaceuticals (SLRX) - Kapitalizatsiyaning foydaga nisbati|PPBT: Narx-foyda koeffitsiyenti|Kompaniya qiymatining sof foydaga nisbati AONC (American Oncology Network, Inc.)|BeOne Medicines (BGNE) - Narxning foydaga nisbati|Checkpoint Therapeutics, Inc (CKPT) - P/E multiplikatori|Narxning foydaga nisbati Elevation Oncology, Inc.|ICAD: Kompaniya qiymatining sof foydaga nisbati|Narxning foydaga nisbati ikenaoncology.com (IKNA)|Narxning foydaga nisbati NTBL (Notable Labs, Ltd.)|P/E multiplikatori VIRX (viracta.com)|MOR - Narx-foyda koeffitsiyenti|NAYA - Narxning foydaga nisbati|Kapitalizatsiyaning sof foydaga nisbati AAPGV